Marshall Wace LLP boosted its holdings in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 1,318.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,213,940 shares of the biopharmaceutical company's stock after purchasing an additional 2,057,864 shares during the quarter. Marshall Wace LLP owned about 2.46% of Chimerix worth $7,705,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. increased its stake in shares of Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock valued at $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Charles Schwab Investment Management Inc. bought a new stake in Chimerix in the fourth quarter valued at $183,000. Rosalind Advisors Inc. acquired a new position in shares of Chimerix during the fourth quarter valued at about $10,614,000. EAM Investors LLC bought a new position in shares of Chimerix during the 4th quarter worth about $786,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix in the 4th quarter valued at about $221,000. 45.42% of the stock is owned by institutional investors and hedge funds.
Chimerix Price Performance
Shares of Chimerix stock opened at $8.54 on Wednesday. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $8.55. The business has a 50 day moving average price of $7.55 and a 200-day moving average price of $4.10. The company has a market cap of $801.09 million, a PE ratio of -9.09 and a beta of -0.17.
Chimerix (NASDAQ:CMRX - Get Free Report) last released its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analysts' expectations of $0.31 million. As a group, research analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.
Insider Activity
In other news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 20,760 shares of company stock worth $91,175 over the last quarter. Insiders own 13.10% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the company. Jefferies Financial Group reaffirmed a "hold" rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reaffirmed a "neutral" rating and set a $8.55 target price (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com initiated coverage on shares of Chimerix in a research report on Wednesday, April 16th. They issued a "hold" rating for the company. Finally, Wedbush restated a "neutral" rating and set a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th.
Read Our Latest Report on CMRX
Chimerix Company Profile
(
Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Further Reading
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix, Inc. (NASDAQ:CMRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
